AbCellera Biologics Inc 8-K, filed Jun 13, 2024
AbCellera Biologics Inc. (ABCL)
8-K
2024-06-13
For: 2024-06-13
View Original
Added on
April 08, 2026
About this 8-K
AbCellera Biologics Inc filed this 8-K on June 13, 2024.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 13, 2024
__________________________________________
(Exact name of registrant as specified in its charter)
__________________________________________
| Not Applicable | ||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
2215 Yukon Street | |||||
| (Address of registrant’s principal executive office) | (Zip code) | ||||
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07 Submission of Matters to a Vote of Security Holders.
AbCellera Biologics Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 13, 2024. As of April 15, 2024, the record date for the Annual Meeting, there were 293,921,356 common shares of the Company outstanding and entitled to vote at the Annual Meeting. The Company’s shareholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2024: (i) to elect Véronique Lecault, Ph.D. and Andrew Lo, Ph.D. as Class I directors of the Company to serve for a three-year term expiring at the Company’s annual meeting of shareholders in 2027 and until his or her successor has been elected and qualified (“Proposal 1”), (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Proposal 2”), and (iii) to approve on a non-binding advisory basis, the compensation of the Company’s named executive offices, or Say-on-Pay (“Proposal 3”).
Proposal 1
The Company’s shareholders approved the election of Véronique Lecault, Ph.D. and Andrew Lo, Ph.D. as Class I directors recommended for election in Proposal 1 at the Annual Meeting. The Company’s shareholders voted for the Class I directors as follows:
| Nominee | For | Against | Abstain | ||||||||
Véronique Lecault, Ph.D. | 167,328,506 | 6,868,582 | 15,059,808 | ||||||||
Andrew Lo, Ph.D. | 152,914,311 | 6,017,047 | 30,325,538 | ||||||||
The broker non-votes for this Proposal 1 totaled 23,405,619 common shares.
Proposal 2
The Company’s shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:
| For | Against | Abstain | ||||||
| 211,978,251 | 306,801 | 377,463 | ||||||
Proposal 3
The Company’s shareholders approved` Proposal 3. The votes cast at the Annual Meeting were as follows:
| For | Against | Abstain | ||||||
| 176,566,724 | 7,454,852 | 5,235,320 | ||||||
The broker non-votes for this Proposal 3 totaled 23,405,619 common shares.
No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 13, 2024 | ABCELLERA BIOLOGICS INC. | |||||||
| By: | /s/ Carl L. G. Hansen | |||||||
| Carl L. G. Hansen, Ph.D. | ||||||||
Chief Executive Officer and Director (Principal Executive Officer) | ||||||||